Enovis Corp (ENOV)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $1.60B
Last updated: Nov 17, 2026 at 11:05 AM ET
Enovis Corp (ENOV) Earnings: Report Dates and Results
Enovis (ENOV) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Enovis reported EPS of $0.78, above the $0.64 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ENOV has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 11.6% above the $0.95 reported for the quarter ended Dec 31, 2025.
ENOV Earnings Call
The latest ENOV earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, ENOV beat 36, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $558.73M, up 1.8% from $548.91M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.78 | $0.64 | N/A | +21.88% | Beat | +4.0% | 13 | 0 up, 2 down | Nov 5, 2026 | $558.73M |
| Jun 30, 2026 | $0.76 | $0.79 | N/A | -3.80% | Miss | -3.8% | 13 | 1 up, 8 down | Aug 6, 2026 | $582.78M |
| Mar 31, 2026 | $0.89 | $0.81 | $0.74 - $0.86 | +9.88% | Beat | +9.9% | 11 | 2 up, 0 down | May 7, 2026 | $589.15M |
| Dec 31, 2025 | $0.95 | $0.81 | $0.79 - $0.97 | +17.28% | Beat | -3.1% | 12 | 2 up, 1 down | Feb 26, 2026 | $575.76M |
| Sep 30, 2025 | $0.75 | $0.65 | $0.61 - $0.67 | +15.38% | Beat | +2.7% | 10 | 5 up, 4 down | Nov 6, 2025 | $548.91M |
| Jun 30, 2025 | $0.79 | $0.74 | $0.62 - $0.78 | +6.76% | Beat | +27.4% | 11 | 5 up, 5 down | Aug 7, 2025 | $564.54M |
| Mar 31, 2025 | $0.81 | $0.74 | $0.71 - $0.78 | +9.46% | Beat | +62.0% | 11 | 1 up, 0 down | May 8, 2025 | $558.83M |
| Dec 31, 2024 | $0.98 | $0.92 | $0.90 - $0.95 | +7.02% | Beat | +24.1% | 11 | 0 up, 1 down | Feb 26, 2025 | $560.98M |
| Sep 30, 2024 | $0.73 | $0.61 | $0.58 - $0.68 | +19.67% | Beat | +30.4% | 11 | 0 up, 0 down | Nov 6, 2024 | $505.22M |
| Jun 30, 2024 | $0.62 | $0.59 | $0.50 - $0.63 | +5.08% | Beat | +1.6% | 11 | 0 up, 1 down | Aug 7, 2024 | $525.16M |
| Mar 31, 2024 | $0.50 | $0.48 | $0.38 - $0.54 | +4.17% | Beat | +13.6% | 10 | 0 up, 0 down | May 2, 2024 | $516.27M |
| Dec 31, 2023 | $0.79 | $0.74 | $0.71 - $0.79 | +6.76% | Beat | +9.7% | 10 | 1 up, 0 down | Feb 22, 2024 | $455.02M |
| Sep 30, 2023 | $0.56 | $0.54 | $0.49 - $0.59 | +3.70% | Beat | -5.1% | 7 | 0 up, 0 down | Nov 7, 2023 | $417.52M |
| Jun 30, 2023 | $0.61 | $0.52 | $0.50 - $0.56 | +17.31% | Beat | +3.4% | 7 | 0 up, 0 down | Aug 3, 2023 | $428.50M |
| Mar 31, 2023 | $0.44 | $0.38 | $0.34 - $0.40 | +15.79% | Beat | +18.9% | 5 | 0 up, 0 down | May 4, 2023 | $406.15M |
| Dec 31, 2022 | $0.72 | $0.66 | $0.52 - $0.69 | +9.09% | Beat | -59.3% | 7 | 0 up, 0 down | Feb 23, 2023 | $408.71M |
| Sep 30, 2022 | $0.59 | $0.48 | $0.44 - $0.50 | +22.92% | Beat | -63.6% | 8 | 0 up, 1 down | Nov 2, 2022 | $383.81M |
| Jun 30, 2022 | $0.59 | $0.50 | $0.49 - $0.52 | +18.00% | Beat | -64.9% | 4 | 0 up, 0 down | Aug 4, 2022 | $395.12M |
| Mar 31, 2022 | $0.37 | $0.35 | $0.34 - $0.36 | +5.71% | Beat | -72.0% | 2 | 0 up, 0 down | May 10, 2022 | $375.46M |
| Dec 31, 2021 | $1.77 | $1.74 | N/A | +1.72% | Beat | +15.7% | N/A | N/A | Feb 22, 2022 | N/A |
| Sep 30, 2021 | $1.62 | $1.61 | N/A | +0.62% | Beat | +31.7% | N/A | N/A | Nov 4, 2021 | $359.92M |
| Jun 30, 2021 | $1.68 | $1.61 | N/A | +4.35% | Beat | +522.2% | N/A | N/A | Jul 28, 2021 | $356.12M |
| Mar 31, 2021 | $1.32 | $1.19 | N/A | +10.92% | Beat | +15.8% | N/A | N/A | Apr 29, 2021 | $879.21M |
| Dec 31, 2020 | $1.53 | $1.49 | N/A | +2.68% | Beat | -16.4% | N/A | N/A | Feb 18, 2021 | N/A |
| Sep 30, 2020 | $1.23 | $1.17 | N/A | +5.13% | Beat | -18.0% | N/A | N/A | Oct 29, 2020 | $805.93M |
| Jun 30, 2020 | $0.27 | $0.31 | N/A | -12.85% | Miss | -83.3% | N/A | N/A | Aug 6, 2020 | $620.36M |
| Mar 31, 2020 | $1.14 | $1.12 | N/A | +1.79% | Beat | -28.3% | N/A | N/A | May 7, 2020 | $816.36M |
| Dec 31, 2019 | $1.83 | $1.67 | N/A | +9.58% | Beat | -11.6% | N/A | N/A | Feb 21, 2020 | $888.37M |
| Sep 30, 2019 | $1.50 | $1.42 | N/A | +5.63% | Beat | -7.4% | N/A | N/A | Oct 31, 2019 | $846.52M |
| Jun 30, 2019 | $1.62 | $1.84 | N/A | -11.96% | Miss | -11.5% | N/A | N/A | Aug 6, 2019 | $908.65M |
| Mar 31, 2019 | $1.59 | $1.48 | N/A | +7.43% | Beat | +10.4% | N/A | N/A | May 8, 2019 | $683.92M |
| Dec 31, 2018 | $2.07 | $1.90 | N/A | +8.95% | Beat | +53.3% | N/A | N/A | Feb 13, 2019 | $227.28M |
| Sep 30, 2018 | $1.62 | $1.58 | N/A | +2.53% | Beat | +28.6% | N/A | N/A | Oct 25, 2018 | $524.02M |
| Jun 30, 2018 | $1.83 | $1.56 | N/A | +17.31% | Beat | +41.9% | N/A | N/A | Aug 6, 2018 | $560.86M |
| Mar 31, 2018 | $1.44 | $1.28 | N/A | +12.50% | Beat | +37.1% | N/A | N/A | May 3, 2018 | $880.92M |
| Dec 31, 2017 | $1.35 | $1.29 | N/A | +4.65% | Beat | -2.2% | N/A | N/A | Feb 6, 2018 | N/A |
| Sep 30, 2017 | $1.26 | $1.23 | N/A | +2.44% | Beat | +7.7% | N/A | N/A | Nov 6, 2017 | $844.51M |
| Jun 30, 2017 | $1.29 | $1.29 | N/A | 0.00% | In line | +4.9% | N/A | N/A | Jul 28, 2017 | $847.96M |
| Mar 31, 2017 | $1.05 | $0.89 | N/A | +17.98% | Beat | +16.7% | N/A | N/A | May 5, 2017 | $733.63M |
| Dec 31, 2016 | $1.38 | $1.32 | N/A | +4.55% | Beat | -9.8% | N/A | N/A | Feb 2, 2017 | $585.14M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.30, up 16.6% from the year before. It was $4.68 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.30 | +16.6% |
| Dec 31, 2024 | $2.83 | +17.9% |
| Dec 31, 2023 | $2.40 | +5.7% |
| Dec 31, 2022 | $2.27 | -64.5% |
| Dec 31, 2021 | $6.39 | +53.2% |
| Dec 31, 2020 | $4.17 | -36.2% |
| Dec 31, 2019 | $6.54 | -6.0% |
| Dec 31, 2018 | $6.96 | +40.6% |
| Dec 31, 2017 | $4.95 | +5.8% |
| Dec 31, 2016 | $4.68 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,200 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,207 | 15 | |
| 2026Q2 | Jun 30, 2026 | 7,023 | 15 | |
| 2026Q1 | Mar 31, 2026 | 6,513 | 14 | |
| 2025Q4 | Dec 31, 2025 | 6,326 | 12 | |
| 2025Q3 | Sep 30, 2025 | 4,497 | 12 | |
| 2025Q2 | Jun 30, 2025 | 6,631 | 11 | |
| 2025Q1 | Mar 31, 2025 | 6,188 | 12 | |
| 2024Q4 | Dec 31, 2024 | 6,772 | 13 |
2026Q3 Earnings Call
Opening remarks
Kyle William Rose Vice President of Investor Relations Good morning, everyone, and thank you for joining us today for our third quarter 2026 earnings conference call. I am Kyle William Rose, Vice President of Investor Relations. Joining me on the call this morning are Damien McDonald, Chief Executive Officer, and Ben Berry, our Chief Financial Officer. Our earnings release was issued earlier this morning and is available in the Investors section of our website, enovis.com. We also posted a slide presentation to accompany today's call on our website. Both the audio and the slide presentation of this call will be archived on our website later today. During this call, we will be making some forward-looking statements about our beliefs and estimates regarding future events and results, including statements related to our pending acquisition of Essential Robotics. These forward-looking statements are subject to risks and uncertainties, including those set forth in the Safe Harbor language in today's earnings release and in our filings with the SEC. Actual results might differ materially from any forward-looking statements that we make today. The forward-looking statements speak only as of today, and we do not assume any obligation to update them except as required by law. For further details regarding any non-GAAP financial measures referenced during this call, the accompanying reconciliation information can be found in our earnings press release and in the appendix of today's slide presentation. With that, let me turn the call over to Damien.
Damien McDonald CEO Thanks, Kyle. Good morning, everyone, and thank you for joining us today. I will start with an overview of our third quarter results across Recon and P&R, and give a short update on Essential Robotics. Ben will then walk through the financials and our outlook for the fourth quarter and the full year before we open the call for questions. In the third quarter, we delivered organic growth of 5%, with 6% organic growth in Recon and 3% in P&R. In U.S. Recon, we grew 5% organically, with extremities up 5% and hips and knees up 3%. In extremities, we are now past the anniversary of the ARG launch, and ARG continues to be a strong growth opportunity for the future. As planned, ARVIS is expanding in shoulder, and we built upon the launch that began in Q2. Shoulder remains a healthy market, and it is where we have one of our leading share positions globally. In hips and knees, Nebula continues to drive growth, with over 80% of new instrumentation sets going to competitive users in the quarter. While we have now annualized the launch of Nebula in the U.S., we remain in the early stages of a multiyear product cycle.
Frequently Asked Questions About ENOV
When is Enovis's next earnings date?
Enovis's next earnings report is expected for Feb 24, 2027.
Did ENOV beat earnings estimates last quarter?
Yes. Enovis reported EPS of $0.78 for the quarter ended Sep 30, 2026, above the $0.64 estimate, a 21.88% surprise.
What EPS do analysts expect from ENOV next quarter?
The consensus EPS estimate for Enovis for the quarter ending Dec 31, 2026 is $1.06 from 15 analysts, with estimates from $0.97 to $1.13.
How often does ENOV beat earnings estimates?
Enovis beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +10.48%.
ENOV pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors